I am a tenure-track Assistant Professor at the Neurology Department and Sealy Institute for Drug Discovery. With a background in Pharmacy and in Neuroscience, my research focuses on underlying biophysical, biomolecular, and physiological mechanisms for either preventing or halting neurodegenerative disorders such as Alzheimer's disease (AD). Further, I work on translating these findings into novel disease-modifying therapies. During my postdoctoral studies, I contributed to the discovery of the effect of the homozygous mutation in the APOE gene, known as the APOE3 Christchurch mutation, in delaying the onset by up to three decades in an individual carrying a very aggressive form of Autosomal Dominant Alzheimer's Disease. The subsequent characterization of novel antibodies capable of mimicking the mechanism of action of this mutation, allowed to propose ApoE interactions as attractive targets for effective disease-modifying therapies for AD. In parallel work, I contributed to the characterization of a second protective genetic variant against familial Alzheimer's disease, the RELN-COLBOS variant, which will contribute to a better understanding of biomolecular mechanisms of resilience against AD.
I am a tenure-track Assistant Professor at the Neurology Department and Sealy Institute for Drug Discovery. With a background in Pharmacy and in Neuroscience, my research focuses on underlying biophysical, biomolecular, and physiological mechanisms for either preventing or halting neurodegenerative disorders such as Alzheimer's disease (AD). Further, I work on translating these findings into novel disease-modifying therapies. During my postdoctoral studies, I contributed to the discovery of the effect of the homozygous mutation in the APOE gene, known as the APOE3 Christchurch mutation, in delaying the onset by up to three decades in an individual carrying a very aggressive form of Autosomal Dominant Alzheimer's Disease. The subsequent characterization of novel antibodies capable of mimicking the mechanism of action of this mutation, allowed to propose ApoE interactions as attractive targets for effective disease-modifying therapies for AD. In parallel work, I contributed to the characterization of a second protective genetic variant against familial Alzheimer's disease, the RELN-COLBOS variant, which will contribute to a better understanding of biomolecular mechanisms of resilience against AD.